Authors
Lars Gullestad
Thor Ueland
John Kjekshus
Ståle H. Nymo
Johannes Hulthe
Pieter Muntendam
John J.V. McMurray, Australian Catholic University
John Wikstrand
Pål Aukrust
Publication Date
2012
Publication Details
Gullestad, L., Ueland, T., Kjekshus, J., Nymo, S. H, Hulthe, J., Muntendam, P., McMurray, J. J, Wikstrand, J. & Aukrust, P. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal,164(6), 878-883. United States: Mosby Inc.. Retrieved from https://doi.org/10.1016/j.ahj.2012.08.021
Abstract
Galectin-3 is a new biomarker involved in inflammation and fibrogenesis and could therefore contribute to myocardial remodeling. We examined the prognostic value of baseline galectin-3 in a substudy involving approximately 30% of participants in the CORONA study.
School/Institute
Mary MacKillop Institute for Health Research
Document Type
Journal Article
Access Rights
ERA Access